Get access to our best features
Get access to our best features
Published 2 months ago

Psychedelic drug MDMA faces questions as FDA considers approval for PTSD

  • The first new PTSD drug in over 20 years, a version of MDMA by Lykos Therapeutics Inc., is up for approval. Federal regulators must approve the mind-altering drug, also known as ecstasy.
  • Lykos Therapeutics Inc., a nonprofit-backed drugmaker, aims to bring psychedelic therapy to the masses with the new PTSD drug based on MDMA.
  • FDA scientists noted significant and lasting PTSD symptom improvements in patients who received MDMA alongside talk therapy, prompting questions about the drug's safety and efficacy.
Insights by Ground AI
Does this summary seem wrong?

0 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 56% of the sources are Center

To view factuality data please Upgrade to Premium


To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)